Complete primary analysis of the IGNYTE clinical trial
Delivered after the deadline (67 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Feb 2023
- Due
- 31 Mar 2024
- Delivered
- 6 Jun 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The primary analysis is expected in Q1 2024, 12 months after the enrollment of the last patient.”
What we found
Evidence strength A What the grades mean
The company announced the topline results from the primary analysis of the IGNYTE clinical trial on June 6, 2024, which is after the original Q1 2024 deadline.
-
A Replimune Group, Inc. 8-K filed 2024-05-16
“The Company is on track to present the 12-month primary analysis by independent central review in Q2 2024.” ✓ confirmed on the page
Market reaction: the shares moved -12.8% against the S&P 500 over the three sessions around the disclosure (15 May 2024 to 20 May 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +91 days
- 2 versions
-
Version 1 · original · stated 9 Feb 2023
Deadline 31 Mar 2024 (“Q1 2024”) · wording expected
-
Version 2 · stated 16 May 2024
Deadline 30 Jun 2024 (“Q2 2024”) · wording expected
“Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Complete
- Deliverable
- IGNYTE clinical trial primary analysis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REPL-002702 · Corrections policy